Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.
White CW, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, Geller NL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Rosenberg Y, Terrin ML; Post Coronary Artery Bypass Graft Trial Investigators. White CW, et al. Among authors: geller nl. Circulation. 2001 Nov 27;104(22):2660-5. doi: 10.1161/hc4701.099730. Circulation. 2001. PMID: 11723015 Clinical Trial.
Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.
Campeau L, Hunninghake DB, Knatterud GL, White CW, Domanski M, Forman SA, Forrester JS, Geller NL, Gobel FL, Herd JA, Hoogwerf BJ, Rosenberg Y. Campeau L, et al. Among authors: geller nl. Circulation. 1999 Jun 29;99(25):3241-7. doi: 10.1161/01.cir.99.25.3241. Circulation. 1999. PMID: 10385497
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.
Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C. Knatterud GL, et al. Among authors: geller nl. Circulation. 2000 Jul 11;102(2):157-65. doi: 10.1161/01.cir.102.2.157. Circulation. 2000. PMID: 10889125 Clinical Trial.
Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of nondiabetic patients. An ACIP database study. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot Investigators.
Caracciolo EA, Chaitman BR, Forman SA, Stone PH, Bourassa MG, Sopko G, Geller NL, Conti CR. Caracciolo EA, et al. Among authors: geller nl. Circulation. 1996 Jun 15;93(12):2097-105. doi: 10.1161/01.cir.93.12.2097. Circulation. 1996. PMID: 8925577 Clinical Trial.
Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study.
Knatterud GL, Bourassa MG, Pepine CJ, Geller NL, Sopko G, Chaitman BR, Pratt C, Stone PH, Davies RF, Rogers WJ, et al. Knatterud GL, et al. Among authors: geller nl. J Am Coll Cardiol. 1994 Jul;24(1):11-20. doi: 10.1016/0735-1097(94)90535-5. J Am Coll Cardiol. 1994. PMID: 8006252 Free article. Clinical Trial.
265 results